韵律疗法对比慢运动健身治疗转移性乳腺癌患者疲劳:随机对照试验研究方案
本研究为瑞士多中心随机对照开放标签两臂试验,计划招募196例伴癌因性疲劳的转移性乳腺癌患者,按1:1随机分配至韵律疗法(ERYT)组或慢运动健身(CoordiFit)主动对照组。主要终点为整个20周干预期间疲劳量表FACIT-F子量表评分较基线的变化。
要点
- 转移性乳腺癌患者癌因性疲劳患病率超过75%,目前无金标准治疗。
- 两组均为13次45分钟标准化治疗,持续20周,频率一致。
- 主要终点为FACIT-F子量表评分在基线、第8、14、20周较基线的变化。
核心结论
- 该研究是首个评估韵律疗法治疗转移性乳腺癌患者疲劳的随机对照试验。
- 若韵律疗法被证实有益,可能对转移性乳腺癌及其他癌症患者、医护人员等产生影响。
研究设计与样本
- 随机对照、开放标签、两臂、多中心瑞士临床试验。
- 计划招募196例伴癌因性疲劳的转移性乳腺癌患者,按1:1随机分配。
- 对照组为主动对照干预CoordiFit,以控制治疗师-患者互动等非预期效应。
关键数值与推荐
- 干预为13次标准化治疗,每次45分钟,前6周每周1次,之后每2周1次,总干预期20周。
- 主要终点为FACIT-F子量表评分在整个干预期间(基线、第8、14、20周测量)较基线的变化。
- 转移性乳腺癌患者癌因性疲劳患病率超过75%。
临床怎么用
- 物理活动可减轻癌因性疲劳并在癌症治疗期间和之后被推荐,但对转移性乳腺癌患者可能负担过重。
- 两种干预均易于学习,训练频率和持续时间安排相同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer-related fatigue (CRF) is the most taxing symptom for many breast cancer patients during and after therapy. In patients with metastatic disease, the prevalence of CRF exceeds 75%. Currently, there is no gold standard for the treatment of CRF. Physical activity can reduce CRF and is recommended during and after cancer treatment, but may be too burdensome for patients with metastatic breast cancer. The aim of this study is to assess the effect on fatigue of eurythmy therapy (ERYT) compared to slow movement fitness (CoordiFit) in metastatic breast cancer patients. METHODS: The ERYT/CoordiFit study is a randomized controlled, open-label, two-arm, multi-center Swiss clinical trial. A sample of 196 patients presenting with CRF will be recruited by oncologists from the departments of clinical oncology at each local study site. All participants will be randomly allocated to the intervention or control group in a 1:1 ratio. The control group is an active control intervention (CoordiFit) in order to control for potential non-intended effects such as therapist-patient interaction and participation in a program. Both ERYT and CoordiFit exercises are easy to learn, and the training sessions will follow the same frequency and duration schedule, i.e., 13 standardized therapy sessions of 45 min (once a week for 6 weeks and then once every second week) during the total intervention period of 20 weeks. The primary endpoint of the study is the change from baseline over the whole intervention period (i.e., including measurements at baseline, weeks 8, 14, and 20) in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) subscale score. DISCUSSION: This study is the first-known randomized clinical trial assessing eurythmy therapy in the treatment of fatigue in metastatic breast cancer patients. Given the distress that fatigue causes patients, it is important to validate treatment options. If eurythmy therapy proves beneficial in CRF as part of this randomized controlled clinical trial, the study may be very impactful with implications not only for metastatic breast cancer patients but also for other cancer patients, health care personnel, scientists, and funding and regulatory bodies. TRIAL REGISTRATION: The ERYT/CoordiFit trial was registered at the US National Institutes of Health (ClinicalTrials.gov) on July 18, 2019, #NCT04024267 , and in the portal for human research in Switzerland on December 3, 2019, #SNCTP000003525 .
引用
- Meier-Girard D, Ribi K, Gerstenberg G, et al. Eurythmy therapy versus slow movement fitness in the treatment of fatigue in metastatic breast cancer patients: study protocol for a randomized controlled trial. Trials. 2020. PMID: 32631427. doi:10.1186/s13063-020-04542-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。